The field of lower urinary tract symptoms (LUTS) consists of several broad and symptom-based diagnoses, including OAB and BPH, which encompass various underlying aetiologies. There is currently an ongoing discussion as to whether the BPH and, in particular, the OAB diagnosis are too all-encompassing and reliant on symptomology, leading to a high level of misdiagnosis and inappropriate treatment. 
Nocturia was recognised by the International Continence Society (ICS) as a standalone symptom in 1999 and defined as"… the complaint that the individual has to wake at night one or more times to void." 2 However, nocturia is also part of the definition of the OAB syndrome, and in 2010 the ICS stated its definition as a condition with characteristic symptoms of "urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology." 3, 4 In the gold-standard diagnostic tool for BPH, the International Prostate Symptom Score (IPSS), there is an optional question on nocturia ("How many times did you typically get up at night to urinate?")
Qualitative studies of the impact of LUTS on patients have revealed that some areas of complaint are shared between OAB, BPH and nocturia whereas other areas seem to be quite distinct and specific to the different conditions. 5, 6 For example, while the number of voids impacts on the bother experienced by patients with OAB, BPH and nocturia, new studies suggest that the bother associated with nocturia is more directly related to its effect on sleep. 7, 8 The consequences that nocturia has for quality of life are probably more closely associated with parameters such as the hours of undisturbed sleep before the first void or the ability to fall back to sleep after visiting the toilet, than with the actual urological symptoms. 9, 10 The aim of this study was to explore the differences in level, underlying causes and consequences of the impact of daytime LUTS vs nocturia to discuss whether patients are being treated for the symptoms which trouble them the most in real life.
| MATERIAL AND ME THODS
Data were drawn from the LUTS Disease-Specific Programme (DSP   ®   ) , a cross-sectional, real-world, multinational survey of physicians (primary care (PCP), urologists and gynaecologists) and their consulting patients in France, Germany, Spain, the UK and the USA.
Thus, the current study reflects how patients are diagnosed in real life when they visit the physicians, as opposed to more traditional retrospective surveys where the analysis is based on a theoretical framework. The diagnoses discussed in this paper are the diagnoses applied by the physicians in real life and have not been changed for analytical purpose by the authors.
The survey was conducted in accordance with the European Pharmaceutical Market Research association 2012 code of conduct for international healthcare market research and the US Health Insurance Portability and Accountability Act 1996.
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Patients had to provide consent for reporting of research findings as required. Data were collected by local fieldwork partners and fully anonymised. Target physicians were identified by the local fieldwork team from public lists of healthcare professionals. All physicians had to have been qualified for between 3 and 35 years.
Primary care physicians and urologists had to be consulted by 4 or more BPH patients and 3 or more OAB patients a week on average; gynaecologists had to be consulted by 6 or more OAB patients a week on average. A full description of the methodology has been published previously. The LUTS Disease-Specific Programme is a non-interventional survey of real-life clinical practice and does not require patients to be tested or otherwise investigated specifically for the survey.
| Patient-reported outcomes
The three PRO questionnaires used in the study were the Overactive Bladder-Questionnaire Short Form (OAB-q SF), the Nocturia Impact Diary (NI-Diary) and the Work Productivity and Activity Impairment (WPAI) questionnaire. They are all frequently used and assess different aspects of impact on the patient.
| The Overactive Bladder-Questionnaire Short Form
The OAB-q SF is a reduced version of the OAB-q, designed to assess patient perception of symptom severity and impact on health-related quality of life (HRQoL) in OAB. 13 It includes a 6-item symptom severity scale and a 13-item HRQoL scale. Both scales have a range of 0-100, however, a higher score on the symptom severity scale indicates greater symptom severity or bother, while a higher score on
What's known
• It is well established that OAB and BPH are both very broad diagnoses, where the treatment satisfaction is limited.
What's new
• This article documents that real-life diagnoses within the area of LUTS are largely overlapping, not aligned with actual symptoms and not adapted to the main cause of bother to the patient. LUTS increases significantly with age and thus many elderly patients are receiving medical treatment for a symptom that does not bother them significantly, while the bothersome symptoms persist.
the HRQoL scale indicates better quality of life. The questionnaire has a 4-week recall period and the responses are rated on a 6-point scale ranging from "not at all" to "a very great deal". Two of the questions are directly related to nocturia.
For evaluation of the underlying causes of symptom severity and bother, the 6 items of the OAB-q SF symptom severity score were collapsed to dichotomous scales of "not bothered" (responses [1] [2] [3] and "bothered" (responses 4-6).
| The Nocturia Impact Diary
The NI-diary is a 12-question disease-specific nocturia scale assessing the impact of nocturia on patients' lives. 14 It includes an 11-item scale assessing the daily impact of nocturia and a single question assessing the overall impact of nocturia. Both scales have range of 0-100 with a higher score indicating greater impact. It is a re-validated and improved version of the disease-specific N-QoL (nocturia QoL). It was developed to be used in conjunction with a voiding diary. Responses are on a 5-point scale ranging from "not at all" to "a great deal."
| Work Productivity and Activity Impairment
The WPAI measures the impact of a given disease on activity impairment and work productivity and is widely used for this purpose.
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The WPAI questionnaire is a self-administered questionnaire with 6 items that investigate 4 aspects of disease impact on patients: absenteeism (work time missed), presenteeism (impairment at work/ reduced on-the-job effectiveness), work productivity loss (overall work impairment; derived from both absenteeism and presenteeism) and activity impairment (impairment outside of work). The WPAI outcomes are expressed as impairment percentages on a 0%-100% scale, with higher numbers indicating greater impairment and less productivity.
| Patient subgroups
The patients were grouped based on physicians actual real-life diagnosis (and were not changed or adapted to fit guidelines afterwards): 
| Statistics
All analyses were performed in Stata v14.1 or higher. 16 Significance was assessed using Mann-Whitney U tests for numeric outcomes (because of their non-parametric distribu- 
| Level of impact
Mean scores on the OAB-q SF, the NI-Diary and the WPAI are stratified by all patient subgroups in Figure 2 . Patients diagnosed with nocturia felt significantly more impacted than patients diagnosed with daytime only LUTS in all scales (P < .0001). Unsurprisingly, this result was most pronounced for the NI-Diary (a nocturia specific scale). As seen in other studies using the WPAI, the productivity level was less impaired than the activity level. On every scale, women with nocturia and daytime symptoms had the worst outcomes of all the diagnostic subgroups.
| Underlying causes of impact
Patients diagnosed with nocturia were significantly more likely to report feeling impacted by their symptoms than patients with daytime LUTS ( Figure 3 ).
Both male and female patients with a nocturia diagnosis reported feeling more bothered by daytime problems (uncomfortable urge to urinate, a sudden urge to urinate, accidental loss of urine, urine loss associated with a strong urge to urinate) than male and female patients without a nocturia diagnosis. As expected, more patients with a nocturia diagnosis reported being bothered by night-time symptoms (night-time urination and waking to urinate) than patients without a nocturia diagnosis.
Most patients with a nocturia only diagnosis (78%) experi-
enced their urinary problems predominantly during sleeping hours. 
| Consequences of impact
In the survey, 60% of patients diagnosed with night-time problems reported being tired "always" or "usually"; this proportion was significantly lower (37%; P < .0001) for patients with daytime problems only.
Only 11% of nocturia only patients, 14% of male nocturia + BPH/OAB patients and 12% of female nocturia + OAB managed to sleep more than 2-3 hours before waking up, whereas 28% of women with OAB only and 29% of men with BPH/OAB only had more than 2-3 hours of undisturbed sleep (P < .0001) (Figure 4 ).
In all diagnostic categories, a large proportion of patients reported that they "always" or "usually" had difficulty getting back to sleep after going to the toilet at night. There was a greater tendency for patients with nocturia in their diagnosis to experience this problem (61% nocturia only, 54% men with nocturia + BPH/OAB, 65% women with nocturia + OAB) than those with daytime symptoms only (46% men BPH/OAB, 55% women OAB only).
| D ISCUSS I ON
This study sought to dissect the level, underlying causes and consequences of LUTS during day or night-time (ie, nocturia) in a group of patients actively seeking help for their urological problems. It was demonstrated that night-and daytime urinary problems indeed impact patients' lives negatively, but a diagnosis of nocturia has significantly more impact on a patient's daily living than a diagnosis of daytime LUTS. A key finding of this study was that nocturia is associated with a specific set of underlying F I G U R E 2 Impact of LUTS as measured by the OAB-q SF, the NI-Diary and the WPAI. * P < .0001 between daytime problems and nighttime problems F I G U R E 3 LUTS impact on typical day-and night-time bother. *P < .001 between daytime problems and night-time problems problems strictly related to sleep, such as feeling tired frequently and having a short initial period of sleep. These findings correspond well with other studies related to the consequences of nocturia.
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Patients in this study, who were not diagnosed with nocturia, surprisingly experience approximately 2 voids per night, raising the question whether they did not feel bothered about nocturia or whether nocturia was absorbed in the broad daytime LUTS diagnosis.
All groups reported difficulties getting back to sleep after a night-time visit to the toilet. This might be a key issue when trying to understand the difference in day-and night-time LUTS and the severity of the consequences of nocturia. 9, 10, 18 These findings are important for the clinic, because they highlight the problems of using non-specific diagnoses of OAB and BPH to incorporate nocturia as well as daytime symptoms. When these quite distinct problems are integrated under the same diagnostic umbrella term, there is a risk that the main underlying causes of impact (ie, night-time voiding and sleep difficulties) experienced by the patient will be overlooked.
It has been reported that physicians tend to underestimate the impact of moderate nocturia. 19, 20 The findings of this study may provide some clues as to the reasons behind this, given that physician focus is traditionally on urological symptoms (ie, the number of voids), whereas patient concerns relate more strongly to the amount and quality of sleep. In particular, LUTS doctors seldom enquire about patients' ability to get back to sleep -a key difficulty for a high proportion of individuals with nocturnal voiding in this study.
We suggest that it may, therefore, be more relevant for physicians to diagnose nocturia and monitor treatment benefit by evaluating sleep end-points rather than simply number of voids.
This study is limited by the fact that the data on impact are all derived from patients with LUTS, and no comparison with the general population is included. As such, it is impossible to view the level of impact and sleep problems in the context of issues reported by the wider non-LUTS population. In addition, the NI-Diary, which was included as one of the tools in this study, is validated for patients with pure nocturia as well as mixed symptoms, but not for pure daytime symptoms. This is likely reflected in the low impact scores derived from the NI-Diary for patients without nocturia. However, as the same pattern of impact across diagnostic subgroups was seen using the OAB-q SF and WPAI questionnaires, this is unlikely to have affected our results substantially.
Across all outcomes described, the observed findings remained consistent when stratified by patients consulting the individual physician types, with the exception of patients consulting a gynaecologist.
These particular results may have differed from the observed findings because of the predominantly female patients with an OAB only diagnosis that were recruited by the gynaecologists as part of the DSP.
| CON CLUS ION
In this population of real-life patients, those who got a diagnosis of nocturia reported significantly higher levels of impact on their lives than their counterparts with a diagnosis of daytime LUTS only. The underlying cause of impact was related to sleep problems such as the lack of undisturbed sleep. More than half of the men and 40% of the women F I G U R E 4 How long after you fall asleep, do you usually wake up wanting to pass urine? *P < .0001 between daytime problems and night-time problems who were diagnosed with OAB or BPH and no nocturia, stated that they experienced their main LUTS problem predominantly at night or equally day and night. Hence, this study underlines the need for more precision in the diagnosis of LUTS and for nocturia to be understood, treated and monitored as a different problem to OAB and BPH to ensure that patients are treated for their most troublesome symptom.
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